| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | -0.017 | 0.9 |
| mRNA | VX-680 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.9 |
| mRNA | BAY 61-3606 | GDSC1000 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | YM-155 | GDSC1000 | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | S-Trityl-L-cysteine | FIMM | pan-cancer | AAC | 0.015 | 0.9 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | selumetinib:JQ-1 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | Pazopanib | FIMM | pan-cancer | AAC | 0.015 | 0.9 |
| mRNA | Dasatinib | FIMM | pan-cancer | AAC | -0.013 | 0.9 |
| mRNA | THZ-2-49 | GDSC1000 | pan-cancer | AAC | -0.0023 | 0.9 |